Aim
To provide the best practice requirements for the management of vitamin B12 deficiency for women receiving treatment and care at WNHS.

Background
B12 deficiency is rare, particularly in pregnancy, however B12 deficiency should be excluded in women with unexplained anaemia\(^1\) or in women who fail to respond to treatment for iron deficiency anaemia. In normal pregnancy, B12 levels fall by 30% by the third trimester of pregnancy.\(^2\) As B12 plays as important role in new tissue development, deficiency can be associated with infertility and repeated miscarriage.\(^3\) Untreated B12 has been associated with adverse neurological outcomes in exclusively breastfed infants.\(^4\)

B12 is generally only found in foodstuffs from animals.\(^5\) Deficiency can occur as a result of insufficient dietary intake or as a result of malabsorption (e.g. post-surgical, pernicious anaemia).\(^3\) The most common cause of B12 deficiency in pregnant women relates to vegetarian or vegan diets.\(^3\)

Women at risk of developing B12 deficiency
- Those with vegetarian, particularly vegan, diet\(^1\)
- Intestinal diseases, previous gastric/ileac resection, history of coeliac disease or inflammatory bowel disease\(^1\)
- Autoimmune disorders (e.g. Graves’ disease, thyroiditis, vitiligo)\(^1\)
- Prolonged use of proton pump inhibitors, H2 receptor antagonists and biguanides\(^1\) as these may interfere with absorption of B12
Signs and symptoms of B12 deficiency
Symptoms are slow to develop as it may take up to 5 years for B12 depletion.³ Symptoms can include neuropsychiatric deficits including paraesthesia, numbness, memory loss, ataxia,⁶ depression, irritability and impaired cognition.³ Symptoms of anaemia may manifest though are uncommon in isolation. Folic acid supplementation may mask (or partially mask) the haematological manifestations of B12 deficiency though does not impact neurological features.
Clinical signs of B12 deficiency include glossitis and mouth ulceration.²

Diagnosis of B12 deficiency
Interpretation of blood results to determine presence and severity of B12 deficiency can be challenging due to the physiological fall in vitamin B12 seen in pregnancy.⁵ Advice from a Haematologist may be required. Vitamin B12 deficiency is diagnosed by holotranscobalamin (HTC, active B12) ≤35pmol/L. Holotranscobalamin is a more reliable marker of low vitamin B12 stores than total vitamin B12 and is most useful when the total vitamin B12 is low or indeterminate.
The full blood count may demonstrate an elevated MCV (abnormally large red blood cells) though this may be masked by co-existing iron deficiency or thalassaemia trait. Neutrophil hypersegmentation may be seen on blood film.²

Screening for B12 deficiency
Screening for B12 deficiency is available to:
- Women at increased risk of B12 deficiency (see above)
- Women with unexplained anaemia
- Women who fail to respond to treatment for iron deficiency anaemia
To screen for vitamin B12 deficiency request ‘serum vitamin B12’. A HTC assay will be automatically performed by the laboratory when the total vitamin B12 is <250pmol/L.

Preventing and treating B12 deficiency
Dietary requirements for B12 are 2.4 microg/day for non-pregnant women.⁷ Supplementation is recommended for vegetarians and vegan women in pregnancy and lactation with a recommended daily intake (RDI) of 2.6microg/day in pregnancy and 2.8microg/day in lactation.⁴,⁷
As B12 deficiency is generally due to impaired absorption, the recommended form of treatment is parenteral B12.³ If there is a strong suspicion of dietary B12 deficiency, a short course of oral B12 (e.g. cyanocobalamin 1000microg/day) should be given. Early repeat B12 assay (e.g. 3-4 weeks) is recommended to ensure response.
Parenteral therapy with hydroxocobalamin (1000microg/1mL), given by intramuscular injection, once weekly for 3 weeks is commonly used.³ In severe B12
deficiency, or if the patient is suffering from neurological symptoms, more frequent dosing is recommended.² Seek Haematologist advice.

It is important to diagnose and correct underlying iron deficiency as treatment with B12 can increase red cell production and exacerbate iron depletion.¹

**Notes on treatment of outpatients**

The patient can arrange for treatment for B12 deficiency directly with her GP, or be provided with a prescription for 3 doses, to be administered at GP practice or on return visits to clinic.

**Follow up of patients following treatment**

If the patient continues to demonstrate a poor haematological response to treatment, consider referral to a Haematologist for further investigations. Women should be followed up and investigated individually by their GP following delivery. If they have received treatment for B12 deficiency during the pregnancy, B12 levels should be reassessed 2 months post-partum to confirm if the levels have returned to the reference ranges.²

---

**References**


---

**Related WNHS policies, procedures and guidelines**

WNHS Obstetrics and Gynaecology clinical guideline: Anaemia and Iron Deficiency: Management in Pregnancy and Postpartum
Keywords: Vitamin, B12, pregnancy, deficiency, screening, preventing, treating

Document owner: Obstetrics and Gynaecology Directorate

Author / Reviewer: Consultant Obstetrician, Consultant Haematologist, Patient Blood Management CNC

Date first issued: October 2015 (v1)

Last reviewed: July 2016 (v2); Oct 2021 (v3)  
Next review date: Oct 2024

Approved by: Medicines and Therapeutics Committee (OOS)

Date: 24/09/2021

 WNHS Health Service Permit Holder under the Medicines and Poisons Regulations 2016

Date: 04/10/2021

Endorsed by: Obstetrics and Gynaecology Directorate Management Committee

Date: 06/10/2021

NSQHS Standards (v2) applicable:
- ☑ 1:Clinical Governance
- ☑ 2:Partnering with Consumers
- ☑ 3:Preventing and Controlling Healthcare Associated Infection
- ☑ 4:Medication Safety
- ☐ 5:Comprehensive Care
- ☐ 6:Communicating for Safety
- ☐ 7:Blood Management
- ☐ 8:Recognising and Responding to Acute Deterioration

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.

Version history

<table>
<thead>
<tr>
<th>Version number</th>
<th>Date</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oct 2015</td>
<td>First version</td>
</tr>
<tr>
<td>2</td>
<td>July 2016</td>
<td>Pathology testing at QEII commenced offering additional test (holoTranscobalamin) for patients with equivocal or low total vitamin B12 levels. This is added by the laboratory if B12 below the consensus cut off.</td>
</tr>
</tbody>
</table>
| 3              | Oct 2021  | • Background, risk list and diagnosis sections updated  
- To screen for deficiency request 'serum vitamin B12'  
- Symptoms of anaemia may manifest though are uncommon in isolation. Folic acid supplementation may mask (or partially mask) the haematological manifestations of B12 deficiency though does not impact neurological features.  
- RDI changed to 2.6mcg/day in pregnancy and 2.8mcg/day in lactation  
- If oral treatment, early repeat B12 assay (e.g. 3-4 weeks) is recommended to ensure response |

This document can be made available in alternative formats on request for a person with a disability.

© North Metropolitan Health Service 2021

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.

www.nmhs.health.wa.gov.au